Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Bingham Farms, Michigan Clinical Trials

A listing of Bingham Farms, Michigan clinical trials actively recruiting patient volunteers.

RESULTS

Found (345) clinical trials

An Open Label Study of CM-AT for the Treatment of Children With Autism

Autism is clearly a significant cause of disability in the pediatric population. Treatment is based on the observation that many children with autism do not digest protein. CM-AT is a proprietary enzyme that is designed as a granulated powder taken three times daily.

Phase

1.17 miles

Learn More »

Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

Ten year safety study examining rates of rare adverse events, child bearing issues, effects of mammography, MRI compliance and results, and long-term benefit of silicone-filled breast implants.

Phase N/A

1.17 miles

Learn More »

Effects of AZD1775 on the PK Substrates for CYP3A CYP2C19 CYP1A2 and on QT Interval in Patients With Advanced Cancer

This is a Phase I, 2-part study (Part A and Part B) in patients with advanced solid tumours. Part A: Part A of this study is an open-label, non-randomised, 2-period design. The treatment starts with the administration of a cocktail of 3 medications: caffeine, omeprazole and midazolam (Day -8), followed ...

Phase

1.17 miles

Learn More »

AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

This is an open-label, non-randomised study designed to provide continued access to AZD1775 for eligible patients with advanced solid tumours who have previously completed an AZD1775 clinical pharmacology study and to investigate the safety of a once daily monotherapy regimen of AZD1775 in patients with advanced solid tumours. All patients ...

Phase

1.17 miles

Learn More »

This Study Will Evaluate the Immunogenicity Reactogenicity and Safety of the Routine Infant Vaccines Pediarix Hiberix and Prevenar 13 When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

The purpose of this study is to assess if there is any immune interference between the Porcine circovirus free (PCV-free) liquid Human rotavirus (HRV) vaccine and routine infant vaccinations currently in use in the US, namely Pediarix, Hiberix and Prevenar 13 as compared to the currently licensed lyophilized formulation of ...

Phase

1.17 miles

Learn More »

Reevaluation Of Systemic Early Neuromuscular Blockade

PRIMARY OBJECTIVE:: To assess the efficacy and safety of early neuromuscular blockade in reducing mortality and morbidity in patients with moderate-severe ARDS, in comparison to a control group with no routine early neuromuscular blockade (NMB). PRIMARY HYPOTHESIS: Early neuromuscular blockade will improve mortality prior to discharge home before day 90, ...

Phase

1.17 miles

Learn More »

Vitamin D to Improve Outcomes by Leveraging Early Treatment

Primary Objective: To assess the efficacy and safety of early administration of vitamin D3 (cholecalciferol) in reducing mortality and morbidity for vitamin D deficient patients at high risk for ARDS and mortality. Primary Hypothesis: Early administration of vitamin D3 (cholecalciferol) will improve all-cause, all-location mortality to day 90 in vitamin ...

Phase

1.17 miles

Learn More »

Efficacy and Safety Study of RAGWITEK (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)

The purpose of this study is to assess the efficacy and safety of MK-3641 (short ragweed [Ambrosia artemisiifolia] extract, MK-3641, SCH 039641, RAGWITEK) sublingual immunotherapy tablets in children aged 5 to 17 years with ragweed-induced allergic rhinitis/rhinoconjunctivitis with or without asthma. The primary hypothesis of this study is that administration ...

Phase

1.59 miles

Learn More »

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension

This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.

Phase

1.59 miles

Learn More »

Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)

This multicenter open-label extension study is designed to evaluate the safety and tolerability of lampalizumab intravitreal injections in participants with GA secondary to age-related macular degeneration (AMD) who completed 96 weeks of treatment in Studies GX29176 (NCT02247479) or GX29185 (NCT02247531). The extension will enroll participants from the parent studies who ...

Phase

1.59 miles

Learn More »